Condition: H3 K27M · Glioma · Sponsor: Jazz Pharmaceuticals
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with dordaviprone (ONC201) following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
This description comes directly from the study's public registry record.
Clinical Trial Disclosure & Transparency · 215-832-3750 · ClinicalTrialDisclosure@jazzpharma.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center | Phoenix, Arizona, United States | Completed |
| Barrow Neurological Institute | Phoenix, Arizona, United States | Active Not Recruiting |
| Phoenix Childrens Hospital | Phoenix, Arizona, United States | Completed |
| Mayo Clinic Arizona | Phoenix, Arizona, United States | Completed |
| UC San Diego Moores Cancer Center | La Jolla, California, United States | Active Not Recruiting |
| Kaiser Permanente Los Angeles Medical Center | Los Angeles, California, United States | Completed |
| UCLA University of California Los Angeles | Los Angeles, California, United States | Completed |
| Children's Hospital of Orange County | Orange, California, United States | Completed |
| University of California Irvine | Orange, California, United States | Active Not Recruiting |
| UCSF Benioff Children's Hospital | San Francisco, California, United States | Active Not Recruiting |
| University of California San Francisco | San Francisco, California, United States | Active Not Recruiting |
| Providence Saint John's Cancer Institute | Santa Monica, California, United States | Active Not Recruiting |
+ 150 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05580562